Q1 2017 13F Holders as of 31 Mar 2017
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Number of holders
-
48
-
Total 13F shares, excl. options
-
39,767,515
-
Shares change
-
+9,950,516
-
Total reported value, excl. options
-
$218,557,000
-
Value change
-
+$55,023,373
-
Number of buys
-
28
-
Number of sells
-
-13
-
Price
-
$5.51
Significant Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q1 2017
54 filings reported holding ADAPY - Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share as of Q1 2017.
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) has 48 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39,767,515 shares
of 1,571,428,571 outstanding shares and own 2.5% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (12,025,999 shares), Capital World Investors (6,792,700 shares), FMR LLC (6,281,650 shares), ORBIMED ADVISORS LLC (1,914,660 shares), Tekla Capital Management LLC (1,466,368 shares), QVT Financial LP (1,360,647 shares), Hillhouse Capital Management, Ltd. (1,190,476 shares), BAILLIE GIFFORD & CO (920,984 shares), AXA (900,000 shares), and Rock Springs Capital Management LP (875,000 shares).
This table shows the top 48 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.